Ensysce Biosciences announces 1-for-15 reverse stock split effective Dec 6, 2024

Ensysce Biosciences, Inc.

Reverse stock split at 1-for-15 ratio, effective 12:01 am on December 6, 2024.
Stockholders approved range of 1:10 to 1:40; board selected 1:15 ratio.
No fractional shares issued; fractional shares rounded up to nearest whole share.
Proportionate adjustments to warrants, stock options, and RSUs will be made.
New CUSIP number for post-split common stock is 293602504.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Ensysce Biosciences, Inc.: Amended Certificate of Incorporation to effect a 1-for-15 reverse stock split (effective 2024-12-06).

Change: charter amendment
Effective: 2024-12-06

Exact text from the filing

On November 27, 2024, Ensysce Biosciences, Inc. (the “Company” or “we” or “our”) filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (as amended to date, the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware to effect a one-for-fifteen (1-for-15) reverse stock split (the “Reverse Stock Split”) of our common stock, par value $0.0001 (the “Common Stock”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-048497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.